Apixaban Prices In The Global Market

By Author: ChemAnalyst
Total Articles: 56
Comment this article

North America
The Apixaban Prices in North America displayed an erratic pattern in the fourth quarter of 2022. Prices were anticipated to increase in the second month of Q4 2022 as a result of rising end-user sector demand and other logistical difficulties. Zero covid rules were implemented, causing trade to be hampered and halted shipments, further influencing the market. Despite greater production costs driven by rising energy prices, the market remained competitive. However, later in December, due to domestic retailers having an adequate supply on hand, Apixaban API prices decreased. By the end of Q4 2022, prices were recorded to drop with values accessed at USD 3252200/MT CFR New York.

APAC
The Asia Pacific Apixaban API market saw high volatility in the fourth quarter of 2022. The Apixaban price rose through the second quarter month due to increased end-user sector demand, several logistical challenges, and rising inflation. The prices at the conclusion of the second month of the fourth quarter were USD 2480020/MT FOB Shanghai. The market remained competitive due to increasing production costs brought ...
... on by rising energy prices and increased domestic output to meet demand from domestic and foreign markets. The tight zero covid policies and frequent lockdowns in the Chinese regions have impacted the market. By the end of December, domestic retailers had enough inventories, causing prices to drop to USD 2466500/MT FOB Shanghai. Additionally, other restrictions, including the removal of the zero covid policy, had an impact on the market.

Europe
Market sentiments Prices of Apixaban API in Europe showed erratic volatility in the fourth quarter of 2022. Prices started to rise at the beginning of Q4 2022 and continued to rise through the second month of the quarter as a result of rising end-user sector demand and other logistical difficulties. Zero covid regulations were put into place, which hindered trade and stopped shipments, which benefitted the European Apixaban market. The market remained competitive despite higher manufacturing costs brought on by rising energy prices. Apixaban API prices did drop later in December, though, as domestic dealers had a sufficient supply on hand. The market remained low in December as a result of loosening policy and weak downstream demand. The figures were retrieved at USD 2855200/MT toward the conclusion of Q4.

ChemAnalyst addresses the key problematic areas and risks associated with chemical and petrochemical business globally and enables the decision-maker to make smart choices. It identifies and analyses factors such as geopolitical risks, environmental risks, raw material availability, supply chain functionality, disruption in technology and so on. It targets market volatility and ensures clients navigate through challenges and pitfalls in an efficient and agile manner. Timeliness and accuracy of data has been the core competency of ChemAnalyst, benefitting domestic as well as global industry in tuning in to the real-time data points to execute multi-billion-dollar projects globally.